SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule |  Andarine / S4 | Ostarine / Enobosarm | Ligandrol / LGD-4033 |
|---|---|---|---|
| Research Topic | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology |
| Pharmacology | Experimental nonsteroidal selective androgen receptor modulator | Nonsteroidal selective androgen receptor modulator candidate | Nonsteroidal selective androgen receptor modulator candidate |
| PrimeCore Class | Class CExperimental / limited evidence | Class BInvestigational | Class BInvestigational |
| Evidence Grade | Grade EPreclinical evidence | Grade BStrong controlled human evidence | Grade BStrong controlled human evidence |
| Evidence boundary | Andarine, S4 and GTx-007 identify an experimental nonsteroidal SARM in the reviewed sources. Evidence is dominated by rat muscle, bone and reproductive-tissue models; these signals do not establish human treatment, performance benefit or long-term safety. FDA records identify marketed andarine products as unapproved drugs and document a product recall involving andarine and ostarine. WADA 2026 prohibits andarine at all times. | Ostarine, enobosarm, GTx-024 and MK-2866 refer to the same investigational SARM candidate in the reviewed literature. Controlled trials reported lean-body-mass signals in selected older adults and cancer populations, but do not establish bodybuilding benefit, long-term safety or product approval. FDA states that no SARM is approved and warns of serious harms. Online naming does not establish identity or amount, and WADA 2026 prohibits enobosarm at all times. | Ligandrol and LGD-4033 identify an investigational nonsteroidal SARM candidate. A 21-day placebo-controlled study in 76 healthy men found an exposure-related lean-mass signal alongside suppression of total testosterone, SHBG and HDL. The study was too small and short to establish clinical or bodybuilding benefit or long-term safety. FDA identifies marketed LGD-4033 products as unapproved drugs, and WADA 2026 prohibits ligandrol at all times. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations |
|
|
|
| Sources | |||
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions